Dave Ricks, Eli Lilly CEO (File photo/AP)
Eli Lilly teams up with KRAS drug pioneer Yi Liu targeting small molecule I/O with $70M upfront
Among the major drugmakers, oncology has become a gold rush in recent years with the big dogs hoovering up research partners along the way. One …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
